Published in Int J Radiat Oncol Biol Phys on February 28, 2012
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging (2012) 1.16
Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys (2013) 1.00
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2014) 0.85
Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol (2015) 0.81
State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol (2015) 0.80
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer (2015) 0.79
PET/CT planning during chemoradiotherapy for esophageal cancer. Radiat Oncol J (2014) 0.78
The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. Clin Oncol (R Coll Radiol) (2014) 0.75
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology (2012) 2.98
Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (2010) 2.97
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A (2004) 2.77
Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med (2009) 2.66
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood (2010) 2.48
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res (2005) 2.09
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol (2010) 2.03
Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods (2007) 1.99
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res (2003) 1.96
Retrospective analysis of artifacts in four-dimensional CT images of 50 abdominal and thoracic radiotherapy patients. Int J Radiat Oncol Biol Phys (2008) 1.87
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2008) 1.81
The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol (2010) 1.76
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res (2006) 1.71
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.69
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.61
Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys (2010) 1.60
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 1.57
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem (2008) 1.57
High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys (2008) 1.57
Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med (2003) 1.57
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (2014) 1.55
Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol (2006) 1.53
Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol (2014) 1.51
Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. J Vasc Interv Radiol (2008) 1.50
Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae. Mol Cancer Res (2005) 1.48
RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat (2007) 1.48
Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol (2005) 1.45
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 1.40
ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol (2015) 1.39
Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med (2004) 1.37
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2007) 1.36
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res (2009) 1.34
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res (2008) 1.34
A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys (2010) 1.33
In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging (2002) 1.32
The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J Biol Chem (2011) 1.31
Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys (2010) 1.30
Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res (2012) 1.28
Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer (2010) 1.27
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol (2012) 1.27
Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology (2007) 1.26
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys (2009) 1.24
A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol (2012) 1.24
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc (2010) 1.21
Investigation of four-dimensional computed tomography-based pulmonary ventilation imaging in patients with emphysematous lung regions. Phys Med Biol (2011) 1.20
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2012) 1.18
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
Molecular imaging techniques in body imaging. Radiology (2007) 1.16
Diagnosis of pancreatic gastrointestinal stromal tumor by EUS guided FNA. JOP (2008) 1.16
Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res (2011) 1.15
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.15
Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res (2007) 1.14
Patterns of care in palliative radiotherapy: a population-based study. J Oncol Pract (2013) 1.13
Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2010) 1.13
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med (2009) 1.12
Commissioning of a novel microCT/RT system for small animal conformal radiotherapy. Phys Med Biol (2009) 1.12
Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol (2013) 1.12
Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol (2006) 1.11
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Transl Oncol (2009) 1.10
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene (2005) 1.10
F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med (2006) 1.09
Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment. Am J Clin Oncol (2009) 1.09
Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2007) 1.08
Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol (2012) 1.08
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One (2010) 1.06
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol (2014) 1.05